BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang B, Zhao YX, Zhang XX, Liao HL, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 2020;19:55. [PMID: 32375806 DOI: 10.1186/s12933-020-01024-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Liang B, Gu N. Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251. Diabetes Care 2022;45:e150. [PMID: 36150058 DOI: 10.2337/dc22-0778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liang B, Li R, Zhang P, Gu N. Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. J Cardiovasc Transl Res 2022. [PMID: 35969357 DOI: 10.1007/s12265-022-10302-4] [Reference Citation Analysis]
3 Zhao X, Liu X, Chen X, Han X, Sun Y, Fo Y, Wang X, Qu C, Yang B. Activation of the sigma-1 receptor exerts cardioprotection in a rodent model of chronic heart failure by stimulation of angiogenesis. Mol Med 2022;28:87. [PMID: 35922746 DOI: 10.1186/s10020-022-00517-1] [Reference Citation Analysis]
4 Liang B, Liang Y, Gu N. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. BMC Cardiovasc Disord 2022;22:261. [PMID: 35689186 DOI: 10.1186/s12872-022-02693-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liang B, Gu N. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01526-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang M, Wu Y, Xu J, Zhang Y, Wei J, Yang H. Time-related accurate investigation of multicomponent drug interventions in heart failure. Phytomedicine Plus 2022;2:100242. [DOI: 10.1016/j.phyplu.2022.100242] [Reference Citation Analysis]
7 Liang B, He X, Gu N. Reassessing Revascularization Strategies in Coronary Artery Disease and Type 2 Diabetes Mellitus. Front Cardiovasc Med 2021;8:738620. [PMID: 34746255 DOI: 10.3389/fcvm.2021.738620] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Liang B, Li R, Bai JY, Gu N. Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda? Front Cardiovasc Med 2021;8:744243. [PMID: 34651030 DOI: 10.3389/fcvm.2021.744243] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Liang B, Liang Y, Li R, Zhang H, Gu N. Integrating systematic pharmacology-based strategy and experimental validation to explore the synergistic pharmacological mechanisms of Guanxin V in treating ventricular remodeling. Bioorg Chem 2021;115:105187. [PMID: 34303037 DOI: 10.1016/j.bioorg.2021.105187] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
10 Liang B, Qu Y, Zhao Q, Gu N. Guanxin V for coronary artery disease: A retrospective study. Biomedicine & Pharmacotherapy 2020;128:110280. [DOI: 10.1016/j.biopha.2020.110280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
11 Liang B, He X, Zhao YX, Zhang XX, Gu N. Advances in Exosomes Derived from Different Cell Sources and Cardiovascular Diseases. Biomed Res Int 2020;2020:7298687. [PMID: 32724810 DOI: 10.1155/2020/7298687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liang B, Gu N. Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE. Cardiovasc Diabetol 2020;19:106. [PMID: 32631360 DOI: 10.1186/s12933-020-01088-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]